Last reviewed · How we verify

Ig NextGen 10% — Competitive Intelligence Brief

Ig NextGen 10% (Ig NextGen 10%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous immunoglobulin (IVIG). Area: Immunology.

phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Ig NextGen 10% (Ig NextGen 10%) — CSL Limited. Ig NextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ig NextGen 10% TARGET Ig NextGen 10% CSL Limited phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens
PRIVIGEN (CSL Behring) PRIVIGEN (CSL Behring) Hospices Civils de Lyon marketed Intravenous immunoglobulin (IVIg) Fc receptors, complement system, pathogenic antigens and antibodies
IGIV3I Grifols IGIV3I Grifols Instituto Grifols, S.A. phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens
IgNextGen 16% IgNextGen 16% CSL Limited phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens
LIV-GAMMA SN Inj.10% LIV-GAMMA SN Inj.10% SK Plasma Co., Ltd. phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens
IV treatment with IGSC, 10% IV treatment with IGSC, 10% Baxalta now part of Shire phase 3 Immunoglobulin replacement therapy Fc receptors, complement system, pathogenic antigens
IGIV GAMMAGARD LIQUID/KIOVIG IGIV GAMMAGARD LIQUID/KIOVIG Baxalta now part of Shire phase 3 Intravenous immunoglobulin (IGIV) Fc receptors, complement system, pathogenic antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous immunoglobulin (IVIG) class)

  1. CSL Limited · 4 drugs in this class
  2. Instituto Grifols, S.A. · 2 drugs in this class
  3. Bio Products Laboratory · 2 drugs in this class
  4. ADMA Biologics, Inc. · 2 drugs in this class
  5. Grifols Biologicals, LLC · 1 drug in this class
  6. Grifols Therapeutics LLC · 1 drug in this class
  7. Kedrion S.p.A. · 1 drug in this class
  8. Octapharma · 1 drug in this class
  9. Oslo University Hospital · 1 drug in this class
  10. SK Plasma Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ig NextGen 10% — Competitive Intelligence Brief. https://druglandscape.com/ci/ig-nextgen-10. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: